Ameriprise
ORMP icon

Ameriprise’s Oramed Pharmaceuticals ORMP Stock Holding History

Ameriprise’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-39,525
Closed -$256K – 4026
2022
Q3 		$256K Buy
39,525
+20,000
+102% +$162K ﹤0.01% 3636
2022
Q2 		$89K Sell
19,525
-12,975
-40% -$69.3K ﹤0.01% 3798
2022
Q1 		$281K Buy
32,500
+3,265
+11% +$33.5K ﹤0.01% 3661
2021
Q4 		$417K Sell
29,235
-4,325
-13% -$90.4K ﹤0.01% 3575
2021
Q3 		$738K Buy
+33,560
New +$572K ﹤0.01% 3279
2021
Q2 		– Sell
-11,972
Closed -$122K – 3949
2021
Q1 		$122K Buy
+11,972
New +$98.3K ﹤0.01% 3755
2014
Q4 		– Sell
-300
Closed -$2K – 4175
2014
Q3 		$2K Buy
+300
New +$2.67K ﹤0.01% 5410

Other funds holding ORMP

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Ameriprise's ORMP Position: Q4 2022 in Review

Ameriprise sold out of Oramed Pharmaceuticals (ORMP) in Q4 2022, closing a stake of 39,525 shares — an estimated $256K sold.

Ameriprise first reported a position in ORMP in Q3 2014 and held it in 7 quarters. The position peaked at $738K in Q3 2021. 77 funds tracked by Wall St. Rank hold ORMP as of Q4 2022.

  • Ameriprise reported no remaining Oramed Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Ameriprise sold 39,525 Oramed Pharmaceuticals shares in Q4 2022, an estimated $256K.
  • Ameriprise first reported a position in Oramed Pharmaceuticals in Q3 2014 and held it in 7 quarters.
  • Ameriprise's Oramed Pharmaceuticals position peaked at $738K in Q3 2021.
  • 77 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2022.

Based on Ameriprise's 13F filing for Q4 2022, filed 14 Feb 2023.